Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 31, 2025 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden...
July 15, 2025 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining...
June 30, 2025 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award...